dihydroxyphenylalanine has been researched along with Arteriosclerosis Obliterans in 1 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
Arteriosclerosis Obliterans: Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vaccaro, E | 1 |
| Solitro, A | 1 |
| Barba, C | 1 |
1 other study available for dihydroxyphenylalanine and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
Levodopa in the treatment of arterial insufficiency of the lower limbs. Clinical and rheographic trial.
Topics: Administration, Oral; Adult; Aged; Arterial Occlusive Diseases; Arteriosclerosis Obliterans; Dihydro | 1973 |